<p>Glenmark Pharmaceutical Europe LTD has launched a generic version of Asthma Drug in Denmark. Seretide Accuhaler which is used to treat asthma.</p><p>The Seretide Accuhaler has been produced by Celon Pharma whereas Glenmark has the marketing and distribution rights for the product across 15 European countries. It has been already said by Glenmark that ithas already received the National Marketing Authorizations for the product in Sweden, Finland, Norway &amp;amp; Iceland.</p><p>&amp;quot;This is Glenmark&#039;s first inhaled respiratory product launch in Europe. Glenmark is the first generic company to receive regulatory approval for substitution in Denmark for its generic of Seretide Accuhaler,&amp;quot; Glenmark Pharmaceuticals Ltd said in a BSE filing.</p><blockquote class="style-3"><p>Glenmark has come in into a premeditated growth and licensing agreement with the Celon Pharma S.A to develop and market a generic version of GlaxoSmithKline&amp;rsquo;s Seretide Accuhaler product&amp;ndash; Fluticasone/Salmeterol dry powder inhaler in 15 European countries.</p></blockquote><p>Glenmark has come in into a premeditated growth and licensing agreement with the Celon Pharma S.A to develop and market a generic version of GlaxoSmithKline&amp;rsquo;s Seretide Accuhaler product&amp;ndash; Fluticasone/Salmeterol dry powder inhaler in 15 European countries.</p><p>Basically Fluticasone/Salmeterol dry powder inhaler is a combined product for the treatment of asthma &amp;amp; chronic obstructive pulmonary disease (COPD), it added.</p><p>Quotng IQVIA data, Glenmark Pharma said Fluticasone/Salmeterol dry powder Inhaler (DPI) had sales of USD 864 million in Europe in the 12-month period ending September 2017. Shares of Glenmark Pharma were trading 0.25 per cent lower at Rs 505 on BSE.</p>